Our range of respiratory medicines means we share a common interest with respiratory specialists.
We focus on supporting the NHS and the Department of Health in managing long-term conditions like asthma and chronic obstructive pulmonary disease (COPD). We address cost-efficient prescribing and develop joined-up care through our Joint Working projects to help improve patient outcomes and also offer value for money.
By recognising aligned goals and objectives in areas of mutual interest, we can work jointly to improve patient outcomes and enhance patient experience. That might be through medicines optimisation, quality improvement, pathway redesign or improvement, innovation or identifying cost efficiencies.
Over five million people in the UK are currently receiving treatment for asthma and the NHS is thought to spend over £1 billion each year treating the condition.1
Chronic obstructive pulmonary disease (COPD) is one of the most common respiratory diseases in the UK. It is estimated that 3 million people have COPD, of whom 2 million are undiagnosed,2 often because people are reluctant to seek medical help, and perhaps ignore their symptoms.
Around 10,000 people are also living with Cystic Fibrosis, it is one of the UK’s most common life-shortening inherited conditions, affecting around one in 2,500 live births.3
"As well as developing and providing our own specialty medicines dedicated to the treatment of asthma, COPD and Cystic Fibrosis, we provide a range of information, consultation and education services to help you manage and improve the service you provide to your patients. This includes inhaler technique training and helping patients understand how compliance and self management of their condition can benefit their overall health."
DuoResp Spiromax® is a multi-dose dry-powder inhaler that contains a fixed dose combination of budesonide and formoterol fumarate dihydrate, and is used for the treatment of asthma and COPD in adult patients. The budesonide is an inhaled corticosteroid which treats the underlying inflammation in asthma and COPD. The formoterol fumarate dihydrate is a rapid-acting and long-lasting β2 agonist for the relief of bronchoconstriction.4
Both of these ingredients are important in achieving good asthma and COPD control. However, a substantial percentage of inhaler users worldwide have inadequate inhaler technique and increased inhalation errors, resulting in poor drug delivery to the lungs.5
"The Spiromax® device is designed to be uncomplicated and user-friendly so adult patients can use it well and their medicine can get to work where it is needed."
DuoResp Spiromax® 160mcg/4.5mcg also has a maintenance and reliever therapy (MART) license.4
DuoResp Spiromax® 160mcg/4.5mcg dry powder inhaler
Each delivered dose (the dose that leaves the mouthpiece of the Spiromax®) contains 160mcg of budesonide and 4.5mcg of formoterol fumarate dihydrate. This is equivalent to a metered dose of 200mcg budesonide and 6mcg of formoterol fumarate dihydrate.4
DuoResp Spiromax® 320mcg/9mcg dry powder inhaler
Each delivered dose (the dose that leaves the mouthpiece of the Spiromax®) contains 320mcg of budesonide and 9mcg of formoterol fumarate dihydrate. This is equivalent to a metered dose of 400mcg budesonide and 12mcg of formoterol fumarate dihydrate.4
Teva Pharma B.V.
Swensweg 5, 2031GA Haarlem
Braltus Zonda® (tiotropium) is indicated as a maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD). Braltus is indicated for use in adults.6
Zonda® is a breath-actuated inhaler.
Teva UK Limited
Hampden Park, Eastbourne, BN22 9AG
For asthma, Teva provides the Qvar® (CFC free beclometasone dipropionate) range of products, including Qvar® Easi-Breathe® (CFC free beclometasone dipropionate), a breath-actuated inhaler. Qvar® is also available in Autohaler® and metered dose inhaler for the prophylactic management of mild, moderate or severe asthma.7
CINQAERO®▼ (reslizumab) is a solution for infusion as an add-on therapy for adult severe eosinophilic asthma.8
Marketing Authorisation Holder:
Teva B.V., Swensweg 5, 2031 GA Haarkem, Netherlands
Tymbrineb® (tobramycin) 300 mg/5 ml Nebuliser Solution is used for the long-term management of chronic pulmonary infection due to Pseudomonas aeruginosa in patients aged six years and older with Cystic Fibrosis.
Tymbrineb® Nebuliser Solution is indicated in adults, adolescents and children aged six years and older.9
We work in partnership with multiple Clinical Commissioning Groups across the country to deliver improved patient outcomes. This is through such Joint Working projects as advanced inhaler training, improving patient education and clinical management of asthma and COPD as well as many more projects. Our Joint Working projects are available on our Joint Working pages.
To discuss potential Joint Working opportunities with Teva within respiratory you can contact us and a representative from Teva will be in touch.
Let's Talk Respiratory is our educational programme of supportive materials, resources and some of the latest news in respiratory for both you and your patients.
Our aim is to support you and encourage you, help empower patients and to make a real difference to the lives of those living with asthma and COPD.
 http://www.asthma.org.uk/asthma-facts-and-statistics accessed 18.04.18
 https://www.nice.org.uk/guidance/qs10/chapter/introduction accessed 18.04.18
 https://www.cysticfibrosis.org.uk/what-is-cystic-fibrosis/faqs accessed 18.04.2018
 DuoResp Spiromax® 320 micrograms/9 micrograms and 160 micrograms/4.5 micrograms inhalation powder - Summary of Product Characteristics
 Price D et al. Resp Med, 2013; 107: 37–46.
 Braltus Zonda® (tiotropium) - Summary of Product Characteristics
 Qvar® (CFC free beclometasone dipropionate) - Summary of Product Characteristics
 Cinqaero® (reslizumab) - Summary of Product Characteristics
 Tymbrineb® (tobramycin) - Summary of Product Characteristics